Healthcare / Diagnostics & ResearchNasdaqCM
$6.16
-0.05 (-0.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-23.6M · quality 59.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$199M
P/E
N/A
•EV/EBITDA
N/A
•ROE
159.6%
↑Gross Margin
56.7%
↑Debt/Equity
-0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-625.6%
FCF / Net income
0.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.1M · net income $-50.2M · FCF $-25.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | $4.1M | $4.1M | $1.9M | $1.5M | $958000.00 | $2.2M | $1.2M | — | — | — | — | — | — |
| Net Income | $-50.2M | $-50.2M | $-60.7M | $-27.8M | $-72.9M | $-64.1M | $-29.9M | $-22.4M | $-15.8M | $-19.4M | $-11.2M | $-8.7M | $-5.0M |
| EBITDA | $-47.9M | $-47.9M | $-59.0M | $-23.1M | $-13.3M | $-52.9M | $-29.4M | — | — | — | — | — | — |
| EPS | -1.65 | -1.65 | -4.66 | -3.75 | -20.00 | -14.40 | — | — | — | — | — | — | — |
| Gross Margin | 56.7% | 56.7% | 39.3% | 27.5% | -1.9% | 64.6% | -52.5% | — | — | — | — | — | — |
| Operating Margin | -754.1% | -754.1% | -1235.9% | -1491.5% | -3011.7% | -2444.3% | -2443.3% | — | — | — | — | — | — |
| Net Margin | -1238.5% | -1238.5% | -3225.0% | -1848.4% | -7609.8% | -2916.2% | -2461.5% | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||
| Debt/Equity | -0.11 | -0.11 | -0.30 | 0.14 | 0.10 | — | — | — | — | 0.42 | — | — | — |
| Current Ratio | 2.54 | 2.54 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-25.4M | $-25.4M | $-21.2M | $-23.6M | $-49.9M | $-38.2M | $-27.2M | $-20.6M | $-11.7M | $-13.5M | $-7.6M | $-4.7M | — |
| Returns | |||||||||||||
| ROE | 159.6% | 159.6% | 494.2% | -135.7% | -212.6% | -98.3% | -89.4% | -72.7% | -460.2% | -440.0% | -113.2% | -83.9% | 464.2% |
| Valuation | |||||||||||||
| P/B | — | — | — | 1.26 | 1.25 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| Revenue Growth | 115.6% | 115.6% | 25.1% | 56.9% | — | 80.8% | — | — | — | — | — | — | — |
| EPS Growth | 64.6% | 64.6% | -24.3% | 81.3% | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+85.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.66 → -1.65
Residual
+85.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.